AC Immune (ACIU) Stock Price

AC Immune Price

NASDAQ·CLOSED
2.26CHF-0.01 (-0.44 %)
Market closed

Over the last 11 years AC Immune grew revenue by 11.1% annually, reaching 27.31 M CHF. Earnings per share have grown at 26.3% per year over the last 5 years. For AC Immune, the net margin of -186.4% is down versus 41.1% a few years ago. The consensus 12-month price target for AC Immune is 7.03 CHF, about 211.1% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 27% above its 52-week low.

AC Immune stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of AC Immune over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AC Immune stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AC Immune's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

AC Immune Stock Price History
DateAC Immune Price
7/31/20262.26 CHF
7/29/20262.27 CHF
7/13/20262.45 CHF
7/10/20262.49 CHF
7/8/20262.52 CHF
6/22/20262.55 CHF
6/18/20262.40 CHF
6/17/20262.34 CHF
6/16/20262.37 CHF
6/15/20262.34 CHF
6/12/20262.31 CHF
6/5/20261.78 CHF
6/4/20261.90 CHF
6/3/20261.88 CHF
6/2/20261.90 CHF
6/1/20261.92 CHF
5/29/20262.09 CHF
5/28/20262.16 CHF
5/27/20262.30 CHF
5/26/20262.29 CHF
5/22/20262.23 CHF
5/21/20262.25 CHF
5/20/20262.28 CHF
5/19/20262.22 CHF
5/18/20262.18 CHF
5/15/20262.20 CHF
5/13/20262.22 CHF
5/4/20262.38 CHF
4/22/20263.06 CHF
4/21/20262.87 CHF
4/20/20262.98 CHF
4/16/20263.07 CHF
4/15/20263.14 CHF
4/14/20263.19 CHF
4/13/20263.30 CHF
4/9/20263.40 CHF
4/8/20263.21 CHF
4/7/20263.11 CHF
4/6/20262.70 CHF
4/2/20262.76 CHF
4/1/20262.79 CHF
3/31/20262.75 CHF
3/30/20262.56 CHF
3/27/20262.70 CHF
3/26/20262.89 CHF
3/25/20262.94 CHF
3/24/20262.86 CHF
3/23/20262.88 CHF
3/20/20262.85 CHF
3/19/20262.95 CHF
3/18/20263.09 CHF
3/17/20263.32 CHF
3/16/20263.13 CHF
3/13/20263.02 CHF
3/12/20263.00 CHF
3/11/20263.06 CHF
3/10/20263.04 CHF
3/9/20262.86 CHF
3/6/20262.79 CHF
3/5/20262.73 CHF
3/4/20262.84 CHF
3/3/20262.91 CHF
3/2/20262.88 CHF
2/27/20262.93 CHF
2/26/20262.96 CHF
2/25/20262.76 CHF
2/24/20262.72 CHF
2/23/20262.53 CHF
2/20/20262.52 CHF
2/19/20262.53 CHF
2/18/20262.62 CHF
2/17/20262.91 CHF
2/13/20262.99 CHF
2/12/20262.93 CHF
2/11/20263.03 CHF
2/10/20263.06 CHF
2/9/20263.11 CHF
2/6/20263.14 CHF
2/5/20262.96 CHF
2/4/20263.06 CHF
2/3/20263.34 CHF
2/2/20263.27 CHF
1/30/20263.19 CHF
1/29/20263.40 CHF
1/28/20263.47 CHF
1/27/20263.54 CHF
1/26/20263.48 CHF
1/23/20263.70 CHF
1/22/20263.63 CHF
1/21/20263.40 CHF
1/20/20263.32 CHF
1/16/20263.51 CHF
1/15/20263.63 CHF
1/14/20263.67 CHF
1/13/20263.70 CHF
1/12/20263.52 CHF
1/9/20263.41 CHF
1/8/20263.44 CHF
1/7/20263.68 CHF
1/6/20263.43 CHF
1/5/20263.52 CHF
1/2/20263.36 CHF
12/31/20253.14 CHF
12/30/20253.15 CHF
12/29/20253.25 CHF
12/26/20253.13 CHF
12/24/20253.13 CHF
12/23/20253.15 CHF
12/22/20253.18 CHF
12/19/20253.03 CHF
12/18/20252.95 CHF
12/17/20252.94 CHF
12/16/20253.29 CHF
12/15/20253.24 CHF
12/12/20253.15 CHF
12/11/20253.22 CHF
12/10/20252.79 CHF
12/9/20252.54 CHF
12/8/20252.78 CHF
12/5/20252.80 CHF
12/4/20252.88 CHF
12/3/20252.85 CHF
12/2/20252.77 CHF
12/1/20252.74 CHF
11/28/20252.99 CHF
11/26/20252.93 CHF
11/25/20252.90 CHF
11/24/20253.08 CHF
11/21/20253.00 CHF
11/20/20252.91 CHF
11/19/20253.12 CHF
11/18/20253.05 CHF
11/17/20253.10 CHF
11/14/20253.29 CHF
11/13/20253.23 CHF
11/12/20253.28 CHF
11/11/20253.39 CHF
11/10/20253.35 CHF
11/7/20253.30 CHF
11/6/20253.45 CHF
11/5/20253.43 CHF
11/4/20253.30 CHF
11/3/20253.18 CHF
10/31/20253.38 CHF
10/30/20253.38 CHF
10/29/20253.84 CHF
10/28/20253.52 CHF
10/27/20253.59 CHF
10/23/20252.81 CHF
10/22/20252.67 CHF
10/21/20252.79 CHF
10/20/20252.95 CHF
10/16/20252.96 CHF
10/15/20253.07 CHF
10/14/20253.07 CHF
10/13/20253.47 CHF
10/9/20253.48 CHF
10/8/20253.52 CHF
10/7/20253.59 CHF
10/6/20253.54 CHF
10/2/20253.13 CHF
10/1/20253.04 CHF
9/30/20252.89 CHF
9/29/20253.04 CHF
9/25/20252.91 CHF
9/24/20252.73 CHF
9/23/20252.52 CHF
9/22/20252.53 CHF
9/18/20252.52 CHF
9/17/20252.46 CHF
9/16/20252.54 CHF
9/15/20252.48 CHF
9/11/20252.38 CHF
9/10/20252.40 CHF
9/9/20252.20 CHF
9/8/20252.20 CHF
9/4/20252.15 CHF
9/3/20252.26 CHF
9/2/20252.21 CHF
8/28/20252.05 CHF
8/27/20252.07 CHF
8/26/20252.10 CHF
8/25/20252.07 CHF
8/21/20252.10 CHF
8/20/20252.14 CHF
8/19/20252.05 CHF
8/18/20252.15 CHF
8/14/20252.13 CHF
8/13/20252.20 CHF
Access this data via the Eulerpool API
Get Free API Key

AC Immune Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
3.90 M CHF
-70.80 M CHF
-70.80 M CHF
Jan 1, 2023
14.80 M CHF
-53.62 M CHF
-54.23 M CHF
Jan 1, 2024
27.31 M CHF
-52.38 M CHF
-50.92 M CHF
Jan 1, 2025 (e)
4.34 M CHF
-2.60 M CHF
-60.20 M CHF
Jan 1, 2026 (e)
35.68 M CHF
-21.41 M CHF
-29.58 M CHF
Jan 1, 2027 (e)
86.33 M CHF
-51.80 M CHF
18.58 M CHF
Jan 1, 2028 (e)
102.63 M CHF
-61.58 M CHF
33.74 M CHF
Jan 1, 2029 (e)
69.89 M CHF
-41.94 M CHF
-2.79 M CHF

AC Immune Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 13, 2026, 8:37 AM
 
REVENUEM CHF
REVENUE GROWTH%
EBITM CHF
EBIT MARGIN%
NET INCOMEM CHF
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
39.0023.0020.007.00110.0015.00–3.0014.0027.004.0035.0086.00102.0069.0075.00
30.00-41.03-13.04-65.001,471.43-86.36––366.6792.86-85.19775.00145.7118.60-32.358.70
18.00-10.00-22.00-49.0044.00-61.00-79.00-70.00-53.00-52.00-2.00-21.00-51.00-61.00-41.00-45.00
46.15-43.48-110.00-700.0040.00-406.67–-2,333.33-378.57-192.59-50.00-60.00-59.30-59.80-59.42-60.00
20.00-7.00-26.00-51.0045.00-61.00-73.00-70.00-54.00-50.00-60.00-29.0018.0033.00-2.00-3.00
100.00-135.00271.4396.15-188.24-235.5619.67-4.11-22.86-7.4120.00-51.67-162.0783.33-106.0650.00
53.9050.1057.1061.8071.1071.9075.0083.6084.6999.6999.6999.6999.6999.6999.6999.69
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales AC Immune generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AC Immune retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AC Immune's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares AC Immune has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AC Immune's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

AC Immune stock margins

The AC Immune margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AC Immune. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AC Immune.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
0.00 %
-398.05 %
-401.95 %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
-1,815.38 %
-1,815.38 %
Jan 1, 2023
0.00 %
-362.30 %
-366.41 %
Jan 1, 2024
0.00 %
-191.80 %
-186.44 %
Jan 1, 2025 (e)
0.00 %
-60.00 %
-1,387.46 %
Jan 1, 2026 (e)
0.00 %
-60.00 %
-82.89 %
Jan 1, 2027 (e)
0.00 %
-60.00 %
21.53 %

AC Immune Stock Revenue, EBIT, Earnings per Share

The AC Immune earnings per share therefore indicates how much revenue AC Immune has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.21 CHF
-0.85 CHF
-0.86 CHF
Jan 1, 2021
0.00 CHF
-1.05 CHF
-0.97 CHF
Jan 1, 2022
0.05 CHF
-0.85 CHF
-0.85 CHF
Jan 1, 2023
0.17 CHF
-0.63 CHF
-0.64 CHF
Jan 1, 2024
0.27 CHF
-0.53 CHF
-0.51 CHF
Jan 1, 2025 (e)
0.04 CHF
-0.03 CHF
-0.60 CHF
Jan 1, 2026 (e)
0.36 CHF
-0.21 CHF
-0.29 CHF
Jan 1, 2027 (e)
0.86 CHF
-0.52 CHF
0.19 CHF

AC Immune business model & stock analysis

AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life.

AC Immune SWOT Analysis

Strengths

1. Strong Research and Development Capabilities: AC Immune SA possesses advanced expertise in neurodegenerative diseases, specifically in the field of Alzheimer's disease.

2. Robust Pipeline: The company has a diversified pipeline of potential therapeutics and diagnostics targeting amyloid and tau proteins, which are known to be key drivers of Alzheimer's.

3. Strategic Partnerships: AC Immune SA has established collaborations with leading pharmaceutical companies, enabling them to leverage their research capabilities and access additional resources.

Weaknesses

1. Dependency on Partnerships: The reliance on partnerships for funding and development support puts AC Immune SA at risk of potential delays or setbacks if collaborations do not meet expectations.

2. Limited Product Portfolio: As a biopharmaceutical company focused on neurodegenerative diseases, AC Immune SA's product portfolio is currently concentrated in a specific therapeutic area, limiting diversification.

3. Regulatory Challenges: Developing treatments for Alzheimer's disease poses significant regulatory hurdles and uncertainties, which may impact the approval process and timelines.

Opportunities

1. Growing Aging Population: The increasing global prevalence of Alzheimer's disease offers significant market potential for AC Immune SA's innovative therapies and diagnostics.

2. Emerging Diagnostic Technologies: Advances in diagnostic technologies may present opportunities for AC Immune SA to develop improved diagnostic tools for early detection and monitoring of Alzheimer's.

3. Potential for Combination Therapies: Collaboration with other pharmaceutical companies to develop combination therapies may enhance treatment efficacy and open new market opportunities.

Threats

1. Intense Competition: AC Immune SA faces competition from large pharmaceutical companies, biotechnology firms, and academic institutions also working on Alzheimer's disease treatments.

2. Economic and Financial Uncertainties: Market volatility, economic downturns, or lack of funding could impact AC Immune SA's ability to secure necessary investments for research and development.

3. Stringent Regulatory Environment: The stringent regulatory requirements for drug approval may result in extended timelines, increased costs, and potential failure to gain regulatory clearance.

AC Immune Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

AC Immune Employees
Details
Date
AC Immune Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

AC Immune Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

AC Immune historical P/E ratio, EBIT multiple, and P/S ratio

AC Immune annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

AC Immune shares outstanding

The number of shares of AC Immune was 99.69 M in 2025. This indicates how many shares AC Immune is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
71.90 M Stocks
Jan 1, 2021
75.00 M Stocks
Jan 1, 2022
83.60 M Stocks
Jan 1, 2023
84.69 M Stocks
Jan 1, 2024
99.69 M Stocks
Jan 1, 2025 (e)
99.69 M Stocks
Jan 1, 2026 (e)
99.69 M Stocks
Jan 1, 2027 (e)
99.69 M Stocks

Current AC Immune forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
5.56 %
Buy
90.00 % (9)
Hold
10.00 % (1)
Sell
0.00 % (0)
12M Price Target
7.03
Last Price
2.26
Currency
CHF
12M Return Potential
211.15 %
LTM Return
0 %

AC Immune Analyst Rating Actions

DateFirmActionRatingReliability
5/4/2026
BTIG
BTIG
MaintainedBuy–
3/16/2026
BTIG
BTIG
MaintainedBuy–
11/4/2025
BTIG
BTIG
MaintainedBuy–
9/8/2025
BTIG
BTIG
MaintainedBuy–
5/1/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
4/3/2025
HC Wainwright& Co.
HC Wainwright& Co.
MaintainedBuy–
4/3/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/14/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
11/15/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
11/6/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

AC Immune Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/3/2026-0.11CHF-6.84 MCHF-2026 Q2
4/23/2026-0.16CHF-275,471.00CHF-2026 Q1
3/12/2026-0.17CHF-1.17 MCHF-2025 Q4
11/14/2024-0.20CHF-1.51 MCHF-2024 Q3
3/14/20240.01CHF-23.29 MCHF-2023 Q4
3/20/2023-0.23CHF-1.01 MCHF-2022 Q4
10/28/2022-0.25CHF-236,829.00CHF-2022 Q3
7/28/2022-0.24CHF-236,829.00CHF-2022 Q2
4/28/2022-0.23CHF-236,829.00CHF-2022 Q1
3/22/20220.10CHF-28.52 MCHF-2021 Q4

EESG©

Eulerpool ESG Scorecard© for the AC Immune stock

64/100
35
Environment
88
Social
70
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees57
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AC Immune shareholder structure

% Name
19.74150%
BVF Partners L.P.
BVF Partners L.P.
1.02042%
Wells Fargo Advisors
Wells Fargo Advisors
0.82494%
Renaissance Technologies LLC
Renaissance Technologies LLC
0.41001%
Acadian Asset Management LLC
Acadian Asset Management LLC
0.37916%
Northern Trust Global Investments Limited
Northern Trust Global Investments Limited
0.36232%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.

AC Immune Beneficial Ownership Filings (SEC 13D/G)

Free Float
61.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
27.00%
Dr. Christof Hettich
Dr. Christof Hettich
SEC ↗
26.80%
Hopp BioTech holding GmbH & Co. KG
Hopp BioTech holding GmbH & Co. KG
SEC ↗
26.80%
Hopp
Hopp
SEC ↗
26.80%
Dr. Friedrich von Bohlen und Halbach
Dr. Friedrich von Bohlen und Halbach
SEC ↗
26.80%
Beteiligungen GmbH & Co. KG
Beteiligungen GmbH & Co. KG
SEC ↗
25.10%
Prof. Dr. Friedrich von Bohlen und Halbach
Prof. Dr. Friedrich von Bohlen und Halbach
SEC ↗
25.10%
Prof. Dr. Christof Hettich
Prof. Dr. Christof Hettich
SEC ↗
25.10%
Oliver Hopp
Oliver Hopp
SEC ↗
25.10%
OH Beteiligungen GmbH & Co. KG
OH Beteiligungen GmbH & Co. KG
SEC ↗
25.10%
Dr. Mathias Hothum
Dr. Mathias Hothum
SEC ↗

AC Immune Executives and Management Board

11 members · avg. age 55 · 36 % women

PP

Prof. Dr. Andrea Pfeifer (67)

Chief Executive Officer, Co-Founder, Director · since 2003

2.72 M CHF

Management

CR

Mr. Christopher Roberts (35)

Chief Financial Officer

–
PD

Mr. Piergiorgio Donati (53)

Chief Technical Operations Officer

–
HD

Mr. Howard Donovan (49)

Chief Human Resources Officer

–
AP

Dr. Anke Post (58)

Chief Medical Officer

–

Board of Directors

DW

Dr. Douglas Williams (67)

Independent Chairman of the Board

191,000.00 CHF
PB

Prof. Dr. Monika Buetler (64)

Independent Vice Chairman of the Board

179,000.00 CHF
MS

Dr. Monica Shaw (47)

Non-Executive Independent Director

138,000.00 CHF
RT

Dr. Roy Twyman

Non-Executive Independent Director

134,000.00 CHF
WL

Dr. Werner Lanthaler

Non-Executive Independent Director

128,000.00 CHF
PJ

Prof. Carl June

Non-Executive Independent Director

124,000.00 CHF

Frequently asked questions about AC Immune

The business model of AC Immune SA focuses on developing innovative therapeutics and diagnostics to prevent and treat neurodegenerative diseases, such as Alzheimer's disease. AC Immune SA employs a unique approach combining precision medicine and immunotherapy to target misfolded proteins, like tau and amyloid-beta, which play a crucial role in the progression of these diseases. By leveraging its proprietary platforms and strategic partnerships, AC Immune SA aims to bring potential disease-modifying treatments and accurate diagnostic tools to market, addressing the unmet needs in neurodegenerative disorders.

AC Immune SA is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of AC Immune SA in the market are companies such as Biogen Inc., Roche Holding AG, and Eli Lilly and Company.

AC Immune SA is a leading biopharmaceutical company with a rich history and background. Founded in 2003, AC Immune has been steadfastly committed to discovering, developing, and delivering innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease. With a strong focus on precision medicine, AC Immune strives to address unmet medical needs by targeting pathological proteins such as tau and alpha-synuclein. Leveraging its state-of-the-art proprietary platforms and strategic collaborations, the company has made significant progress in advancing its robust pipeline of therapeutics and diagnostics. AC Immune's unwavering dedication to improving patients' lives continues to drive its pioneering research and development efforts in the field of neurodegenerative diseases.

AC Immune SA, a renowned biotech company, has achieved several significant milestones. It has successfully advanced its proprietary clinical-stage pipeline, focusing on neurodegenerative diseases like Alzheimer's and Parkinson's. AC Immune has also established strategic collaborations with renowned pharmaceutical companies, reinforcing its position in the industry. The company has achieved positive clinical trial results for its innovative therapeutic candidates, demonstrating promising efficacy and safety profiles. AC Immune's dedication to pioneering precision medicine approaches and its strong focus on research and development have been instrumental in its continuous growth and recognition in the field of neurodegenerative diseases.

AC Immune SA is primarily present in multiple countries and regions across the globe. Some of the key areas where the company has a significant presence include Switzerland, where AC Immune SA is based, as well as the United States, where it operates through its subsidiaries. Additionally, AC Immune SA has a growing presence in various European countries, including France, Germany, and the United Kingdom. With its global reach, AC Immune SA is continuously expanding its footprint and partnerships to advance its mission in pioneering precision medicine for neurodegenerative diseases.

AC Immune SA represents a set of core values and a corporate philosophy that guide its actions and decision-making. The company is committed to advancing precision medicine to combat neurodegenerative diseases. AC Immune SA focuses on the discovery, development, and commercialization of innovative therapies targeting misfolded proteins, with a particular emphasis on Alzheimer's disease. By leveraging its deep scientific expertise and collaborative approach, AC Immune SA strives to make a meaningful impact on patients' lives. The company's dedication to scientific excellence, integrity, innovation, and patient-centeredness drives its pursuit of groundbreaking treatments and solutions for neurodegenerative disorders.

Analysts currently set an average price target of 7.45 CHF for the AC Immune stock (median: 7.03 CHF), implying +229.5 % versus the latest price. The consensus is based on 10 analyst ratings.

AC Immune Analyst Price Targets 2026

10 analysts currently rate the AC Immune stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect AC Immune to generate revenue of 35.68 M CHF and earnings per share of -0.30 CHF.

AC Immune Analyst Price Targets 2026

Converted at the current exchange rate, the AC Immune share trades at 2.41 EUR (2.26 CHF).

The AC Immune share (ACIU) is listed on 4 stock exchanges, including: NASDAQ (ACIU), Frankfurt (IMR.F), München (IMR.MU), Düsseldorf (IMR.DU).

AC Immune SA is a biotechnology company that focuses on the development of innovative therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). The company covers several areas, including research and development, clinical development, production, and distribution of medications. Currently, AC Immune SA is working on several product candidates in different phases of clinical development. This includes a range of monoclonal antibodies and small molecules that target specific neurodegenerative receptors and proteins such as beta-amyloid and tau protein. AC Immune SA's product candidates aim to eliminate disease-causing proteins by supporting the immune defense of the body or directly inhibiting protein formation. A major product of AC Immune SA is the monoclonal antibody ACI-24, which targets beta-amyloid, a buildup of proteins that plays an important role in Alzheimer's disease. ACI-24 is currently in phase II of clinical development. Another product candidate of AC Immune SA is the monoclonal antibody ACI-35, which targets tau protein, which promotes the formation of β-amyloid. ACI-35 is in preclinical development. Furthermore, AC Immune SA utilizes its proprietary platform technology to advance the development of biomarkers that can be used in the diagnosis of neurodegenerative diseases. AC Immune SA has a number of partnerships with pharmaceutical companies such as Roche, Genentech, and Johnson & Johnson to market and further develop its products and technologies. AC Immune SA pursues a business model that aims to manufacture patented therapeutic agents tailored to the needs of patients with neurodegenerative diseases. This business model also includes close collaboration with other pharmaceutical companies and academic institutions to unlock additional clinical benefits and accelerate commercialization. Through its product pipeline and platform technology, as well as strategic partnerships, AC Immune SA offers its customers and patients a comprehensive portfolio of therapeutic products and services aimed at revolutionizing the treatment of neurodegenerative diseases. Overall, AC Immune SA has earned an excellent reputation through its continuous search for innovative solutions and its commitment to collaboration in a highly competitive market.

The expected revenue of AC Immune is 35.68 M CHF. This figure is based on current financial data and reflects the company's business performance.

The expected profit of AC Immune is -29.58 M CHF. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of AC Immune is currently -7.62. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AC Immune stock.

The price-to-sales ratio (P/S) of AC Immune is currently 6.31. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AC Immune stock.

The Eulerpool Quality Score for AC Immune is 2/10.

The ISIN of AC Immune is CH0329023102. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of AC Immune is A2AR5F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of AC Immune is ACIU. The ticker symbol is used to trade AC Immune shares on the stock exchange.

AC Immune paid dividends every year for the past 0 years.

AC Immune is assigned to the 'Health' sector.

The dividends of AC Immune are distributed in CHF.

All fundamentals and in-depth analysis of AC Immune

Our stock analysis for AC Immune stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

AC Immune Stock
AC Immune Revenue→
AC Immune Stock
AC Immune Net Income→
AC Immune Stock
AC Immune P/E→
AC Immune Stock
AC Immune P/S→
AC Immune Stock
AC Immune EBIT→
AC Immune Stock
AC Immune Dividend→
AC Immune Stock
AC Immune Directors Dealings→
AC Immune Stock
AC Immune Stocks→
AC Immune Stock
AC Immune Market capitalization→
AC Immune Stock
AC Immune Debt→
AC Immune Stock
AC Immune Liabilities→
AC Immune Stock
AC Immune Equity→
AC Immune Stock
AC Immune AAQS→
AC Immune Stock
AC Immune Employees→
AC Immune Stock
AC Immune ROE→
AC Immune Stock
AC Immune ROA→
AC Immune Stock
AC Immune ROCE→
AC Immune Stock
AC Immune News→
AC Immune Stock
AC Immune Analyst Price Targets→

Health Stocks

Acadia Healthcare CompanyAbsciACADIA PharmaceuticalsAbnova TaiwanAcarixABL BioACC Aviation HoldingsAbivax SA American Depositary SharesAccendra HealthAbivaxAccent MicrocellAbionyx PharmaAll Stocks A–Z →